Simple predictors for the completion of scheduled gemcitabine‑cisplatin regimens based on real‑world urothelial cancer data

Shinohara,Mayuka; Hata,Shinro; Inoue,Toru; Shibuya,Tadamasa; Ando,Tadasuke; Mimata,Hiromitsu; Shin,Toshitaka

doi:10.3892/mco.2024.2735

May-2024 Volume 20 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2024 Volume 20 Issue 5

Full Size Image

Article Open Access

Simple predictors for the completion of scheduled gemcitabine‑cisplatin regimens based on real‑world urothelial cancer data

Authors:
- Mayuka Shinohara
- Shinro Hata
- Toru Inoue
- Tadamasa Shibuya
- Tadasuke Ando
- Hiromitsu Mimata
- Toshitaka Shin
View Affiliations / Copyright

Affiliations: Department of Urology, Oita University Faculty of Medicine, Yufu, Oita 879‑5593, Japan

Copyright: © Shinohara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 37
|
Published online on: April 1, 2024

https://doi.org/10.3892/mco.2024.2735
Expand metrics +

Abstract

Gemcitabine plus cisplatin (GC) is the standard first line of chemotherapy for urothelial carcinoma. However, it is often difficult to complete scheduled GC therapy because of real‑world adverse events. Therefore, the reasons behind delays, scheduled cancelations and determined predictive factors for completing scheduled GC therapy were retrospectively analyzed. Patients diagnosed with locally advanced or metastatic urothelial carcinoma from 2009 to 2020 received a 4‑week GC therapy schedule in Oita University Hospital. Information was retrospectively extracted from medical records and all cycles were divided into two groups: One wherein all treatments were administered and completed on schedule and the other wherein treatment was either delayed or canceled in during the treatment schedule. Predictive factors were then statistically extracted between the two groups. In total, 70 patients received 201 cycles of a 4‑week scheduled GC therapy. Of the 201 cycles, a total of 68 (33.8%) completed all scheduled treatments, while 133 (66.1%) did not complete the treatment as scheduled. In the group where administration was not completed on schedule, the factors of male, ureteral cancer, lower stage, <90% of gemcitabine and cisplatin dosage, solitary kidney, high creatinine level, low estimated glomerular filtration rate level, low platelet count and high alkaline phosphatase level at the initiation of each cycle were more significant. Additionally, the lowest anticancer drug percentage administration was on day 15. From these results, predictive factors for patients with various backgrounds who completed the scheduled 4‑week GC therapy based on real‑world data were identified. This information can be useful for clinical physicians when deciding the course of treatment.

View Figures

View References

1	Kayahan N, Karaca M, Satış H, Yapar D and Özet A: Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. Turk J Med Sci. 51:1727–1732. 2021.PubMed/NCBI View Article : Google Scholar
2	Fujiwara M, Hayashi T, Takeda H, Yuasa T, Komai Y, Numao N, Yamamoto S, Fukui I, Kouno T and Yonese J: Cisplatin, gemcitabine, and paclitaxel as a salvage second-line therapy for metastatic germ-cell cancer. Clin Genitourin Cancer. 19:e6–e11. 2021.PubMed/NCBI View Article : Google Scholar
3	Hanna KS, Campbell M, Kolling A, Husak A, Sturm S, Bello D and Blake K: Updates in the management and future landscape of urothelial carcinoma. J Oncol Pharm Pract. 27:435–444. 2021.PubMed/NCBI View Article : Google Scholar
4	von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005.PubMed/NCBI View Article : Google Scholar
5	Kim HS, Lee S and Kim JH: Real-world evidence versus randomized controlled trial: Clinical research based on electronic medical records. J Korean Med Sci. 33(e213)2018.PubMed/NCBI View Article : Google Scholar
6	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Version 4. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed November 9, 2016.
7	Wu M, Lin P, Xu L, Yu Z, Chen Q, Gu H and Liu C: Prognostic role of serum lactate dehydrogenase in patients with urothelial carcinoma: A systematic review and meta-analysis. Front Oncol. 10(677)2020.PubMed/NCBI View Article : Google Scholar
8	Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S, Okubo Y, Yamamoto S, Yonese J and Fukui I: Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. BJU Int. 110:1478–1484. 2012.PubMed/NCBI View Article : Google Scholar
9	von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000.PubMed/NCBI View Article : Google Scholar
10	Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, et al: Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int. 112:453–461. 2013.PubMed/NCBI View Article : Google Scholar
11	Sheth KR, Haddad AQ, Ashorobi OS, Meissner MA, Sagalowsky AI, Lotan Y and Margulis V: Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma. Urol Oncol. 34:418.e419–418.e16. 2016.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Simple predictors for the completion of scheduled gemcitabine‑cisplatin regimens based on real‑world urothelial cancer data

This article is mentioned in:

Abstract

Figure 1

Related Articles